Thromboxane, prostacyclin, and leukotrienes in cerebral ischemia

S. T. Chen; C. Y. Hsu; E. L. Hogan; P. V. Halushka; O. I. Linet; F. M. Yatsu

doi:10.1212/WNL.36.4.466

Thromboxane, prostacyclin, and leukotrienes in cerebral ischemia

S. T. Chen, C. Y. Hsu, E. L. Hogan, P. V. Halushka, O. I. Linet, F. M. Yatsu

Medical University of South Carolina

Research output: Contribution to journal › Journal Article › peer-review

107 Scopus citations

Abstract

Our understanding of the biochemistry and biologic actions of AA metabolites has been greatly expanded in recent years. The discoveries of TXA₂, PGI₂, and LTs have fostered new concepts of the pathophysiology of cerebral ischemia. New approaches to treatment of ischemia include seeking an optimal dose of aspirin, developing drugs that selectively inhibit or antagonize TXA₂ or LTs, and administering PGI₂ or its analogues. Altering the dietary content of essential fatty acids for prophylaxis is also being studied. Though the results of this thrust are still preliminary, the exploration of these therapeutic strategies in cerebrovascular disorders based on further understanding of the pathophysiologic roles of TXA₂, PGI₂, LTs and probably other AA metabolites is anticipated with some optimism.

Original language	English
Pages (from-to)	466-470
Number of pages	5
Journal	Neurology
Volume	36
Issue number	4
DOIs	https://doi.org/10.1212/WNL.36.4.466
State	Published - 1986
Externally published	Yes

Access to Document

10.1212/WNL.36.4.466

Cite this

@article{8f97a12ebb0c427f9a5986eb3966c6d3,

title = "Thromboxane, prostacyclin, and leukotrienes in cerebral ischemia",

abstract = "Our understanding of the biochemistry and biologic actions of AA metabolites has been greatly expanded in recent years. The discoveries of TXA2, PGI2, and LTs have fostered new concepts of the pathophysiology of cerebral ischemia. New approaches to treatment of ischemia include seeking an optimal dose of aspirin, developing drugs that selectively inhibit or antagonize TXA2 or LTs, and administering PGI2 or its analogues. Altering the dietary content of essential fatty acids for prophylaxis is also being studied. Though the results of this thrust are still preliminary, the exploration of these therapeutic strategies in cerebrovascular disorders based on further understanding of the pathophysiologic roles of TXA2, PGI2, LTs and probably other AA metabolites is anticipated with some optimism.",

author = "Chen, {S. T.} and Hsu, {C. Y.} and Hogan, {E. L.} and Halushka, {P. V.} and Linet, {O. I.} and Yatsu, {F. M.}",

year = "1986",

doi = "10.1212/WNL.36.4.466",

language = "英语",

volume = "36",

pages = "466--470",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Thromboxane, prostacyclin, and leukotrienes in cerebral ischemia

AU - Chen, S. T.

AU - Hsu, C. Y.

AU - Hogan, E. L.

AU - Halushka, P. V.

AU - Linet, O. I.

AU - Yatsu, F. M.

PY - 1986

Y1 - 1986

N2 - Our understanding of the biochemistry and biologic actions of AA metabolites has been greatly expanded in recent years. The discoveries of TXA2, PGI2, and LTs have fostered new concepts of the pathophysiology of cerebral ischemia. New approaches to treatment of ischemia include seeking an optimal dose of aspirin, developing drugs that selectively inhibit or antagonize TXA2 or LTs, and administering PGI2 or its analogues. Altering the dietary content of essential fatty acids for prophylaxis is also being studied. Though the results of this thrust are still preliminary, the exploration of these therapeutic strategies in cerebrovascular disorders based on further understanding of the pathophysiologic roles of TXA2, PGI2, LTs and probably other AA metabolites is anticipated with some optimism.

AB - Our understanding of the biochemistry and biologic actions of AA metabolites has been greatly expanded in recent years. The discoveries of TXA2, PGI2, and LTs have fostered new concepts of the pathophysiology of cerebral ischemia. New approaches to treatment of ischemia include seeking an optimal dose of aspirin, developing drugs that selectively inhibit or antagonize TXA2 or LTs, and administering PGI2 or its analogues. Altering the dietary content of essential fatty acids for prophylaxis is also being studied. Though the results of this thrust are still preliminary, the exploration of these therapeutic strategies in cerebrovascular disorders based on further understanding of the pathophysiologic roles of TXA2, PGI2, LTs and probably other AA metabolites is anticipated with some optimism.

UR - http://www.scopus.com/inward/record.url?scp=0022536058&partnerID=8YFLogxK

U2 - 10.1212/WNL.36.4.466

DO - 10.1212/WNL.36.4.466

M3 - 文章

AN - SCOPUS:0022536058

SN - 0028-3878

VL - 36

SP - 466

EP - 470

JO - Neurology

JF - Neurology

IS - 4

ER -

Thromboxane, prostacyclin, and leukotrienes in cerebral ischemia

Abstract

Access to Document

Other files and links

Fingerprint

Cite this